Shukra Pharmaceuticals Limited – Fundamental Equity Research Report
Date: February 4, 2026 (Current Context)
Market Price (CMP): ₹38.50 – ₹54.15 (High Volatility Observed across sources)
Market Cap: ₹1,700 Cr – ₹2,370 Cr (Micro-Small Cap)
1️⃣ Business Model & Work (Kya karti hai company?)
Shukra Pharmaceuticals ek integrated pharmaceutical manufacturer hai jo domestic aur international markets ke liye kaam karti hai.
- Core Business: Company mainly Antibiotics (Penicillin, Cephalosporin, Carbapenems) aur General formulations (Tablets, Capsules, Injections) manufacture karti hai.
- Manufacturing Facility: Inka plant Rakanpur, Gujarat me hai jo WHO-GMP certified hai.
- Revenue Source:
- Contract Manufacturing: Dusri badi pharma companies (Clientele includes names like Zydus, Intas in past lists) ke liye dawaiyan banana.
- Exports: African aur Asian countries me export focus hai.
- New Ventures: Haal hi me company ne healthcare tech aur laboratory testing me bhi kadam rakha hai.
- Key Products: Azithromycin, Ciprofloxacin, Amoxycillin jaise generic antibiotics.
2️⃣ Industry & Sector Analysis
- Sector Status: Indian Generic Pharma sector Secular growth phase me hai, kyunki dawaiyon ki demand economic cycle par depend nahi karti.
- Growth Drivers:
- China + 1 Strategy: Global companies India se sourcing badha rahi hain.
- Govt PLI Schemes: Domestic API production ko boost mil raha hai.
- Competitive Intensity: Extremely High. Ye ek fragmented market hai jahan thousands of small players same generic molecules bana rahe hain (Commodity business).
- Competitors: Syschem, Bafna Pharma, aur non-listed small contract manufacturers.
3️⃣ Latest Financial Performance (Consolidated)
⚠️ Critical Observation: Screener aur Yahoo Finance data me Revenue Drop clear dikh raha hai latest quarters me. Company high valuation par trade kar rahi hai despite weak sales.
Financial Trend (Figures in ₹ Crores except Ratios)
| Particulars | FY 2022 | FY 2023 | FY 2024 | Latest Qtr (Dec/Sep) | Trend Signal |
| Revenue (Sales) | 20 Cr | 59 Cr | 75 Cr | ~6 – 11 Cr | 🔻 Declining Trend |
| Operating Profit | 3 Cr | 5 Cr | 19 Cr | ~1 – 4 Cr | ⚠️ Volatile |
| Net Profit (PAT) | 0.8 Cr | 4.4 Cr | 18.5 Cr | ~2 – 3 Cr | 📉 High Variance |
| OPM % | 14% | 9% | 26% | 30%+ | ❇️ Margins Improved |
| EPS (₹) | 0.02 | 0.28 | 0.42 | 0.07 | 🔻 Low Earnings |
| ROE % | 2% | 16% | 32% | — | 📉 Moderating |
Note: Latest Sales run-rate (approx 25-40 Cr annualized) pichle saal (75 Cr) se kam lag raha hai based on quarterly trajectory.
- Debt Status: Company virtually Debt Free hai (Debt/Equity < 0.1). Ye ek positive sign hai.
- Cash Flow: Cash flow from operations positive raha hai FY24 me, lekin latest drop concern hai.
4️⃣ Management & Shareholding (Latest Available Data)
- Promoters:~50.95% (Stable).
- ⚠️ Important: Pichle kuch quarters me Promoter holding constant hai, jo confidence show karta hai.
- Pledging: 0% (Promoters ne shares girvi nahi rakhe hain – Good Sign).
- FII / DII:
- DIIs/FIIs: 0% – 0.11%. Institutional holding na ke barabar hai. Ye stock purely retail aur HNI/Operators ke haath me hai.
- Public: ~49%. High retail participation high volatility create karta hai.
5️⃣ Valuation (Price vs Value)
⚠️ Overvaluation Alert: Stock apne fundamentals se kaafi mehnga lag raha hai.
| Metric | Shukra Pharma | Industry Avg (Small Cap) | Comment |
| P/E Ratio | 145x – 198x | 25x – 30x | Extremely Expensive |
| P/B Ratio | 26x | 3x – 5x | Very High |
| EV / EBITDA | ~99x | 15x – 20x | Unjustified |
- Interpretation: Company ka Market Cap (~1,700 Cr) uski Sales (~50-70 Cr) ke comparison me 25x Sales par trade ho raha hai. Usually, pharma companies 3x-5x Sales par trade karti hain.
- Peer Comparison: Sun Pharma, Cipla jaise giants bhi 30-40 P/E par hain. Shukra ka 150+ P/E valuation sustain karna mushkil hai unless profit 5 guna badh jaye.
6️⃣ Future Growth Triggers (Possibilities)
- Capacity Utilization: Agar Rakanpur facility full capacity par chalti hai to revenue wapas 100 Cr+ ja sakta hai.
- New Subsidiary: Shukra Healthtech (Subsidiary) ke through naye segments enter karne ki news hai, par abhi numbers me reflect nahi hua hai.
- Export Markets: African tenders agar milte hain to volume boost ho sakta hai.
7️⃣ Present Situation (Outlook)
- Stock Phase: Speculative / Momentum Phase. Stock price earnings growth se drive nahi ho raha, balki liquidity aur operator activity se drive ho raha lagta hai.
- Results: Latest results (Dec/Sep quarters) me revenue growth negative thi (YoY). Profit maintain karne ke liye margins badhaye gaye hain, par top-line growth missing hai.
- Outlook: Short-term me volatility rahegi. Long-term fundamental growth abhi prices me already priced-in hai (aur shayad usse bhi zyada).
8️⃣ Risk & Red Flags (Must Read)
- Valuation Risk: 150x P/E ratio small-cap ke liye sustainable nahi hota. Koi bhi choti negative news stock ko crash kar sakti hai.
- Revenue Drop: FY24 ke high base ke baad, current quarters me sales girna business slowdown ka sanket hai.
- Low Institutional Interest: Koi bhi bada Mutual Fund ya FII invest nahi kar raha, jo quality check ka sabse bada filter hota hai.
- Micro-Cap Volatility: Daily circuits (Upper/Lower) lagne ka risk rehta hai, liquidity sukh sakti hai.
9️⃣ Final Verdict
- Summary: Shukra Pharmaceuticals ek debt-free micro-cap company hai, lekin current valuation (Market Cap > ₹1700 Cr vs Sales < ₹80 Cr) fundamentals se disconnected lag rahi hai.
- Conservative Investors: AVOID. High valuation aur revenue inconsistency safety provide nahi karte.
- Long-Term Investors: Wait for correction. Jab tak P/E ratio reasonable levels (30-40x) par nahi aata, entry risky hai.
- Aggressive / Traders: Sirf momentum play ke liye suitable hai with strict Stop Loss. Fundamentals currently price ko support nahi kar rahe.
Target Range: Valuation techniques (Relative Valuation) suggest Fair Value is significantly lower than CMP. Downside risk > Upside potential fundamentally.
Disclaimer: Ye article sirf educational purpose ke liye hai. Kisi bhi nivesh se pehle apne Financial Advisor se salah zarur lein.